Gestational diabetes is usually diagnosed between the 24th and 28th week of pregnancy, which may be too late to counteract some long-lasting harm to the pregnant person and child.
During pregnancy there are changes in glucose metabolism—the way glucose, often called blood sugar, is used in the body—to meet the needs of the developing fetus, but the details of these changes are unknown. With sites around the country, the Glycemic Observation and Metabolic Outcomes in Mothers and Offspring study, or GO MOMs, aims to fill in these knowledge gaps. The study will enroll about 2,150 people without diabetes and in their first trimester of pregnancy. Funded by NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GO MOMs will use continuous glucose monitoring technology to map blood glucose levels throughout pregnancy.
“We are extremely excited to participate in GO MOMs, a study that will forever change how we identify abnormal glucose metabolism in pregnancy. The infrastructure and collaboration that the Hassenfeld Institute has fostered is one of the main reasons that we were able to secure this opportunity for patients across Rhode Island,” said Erika Werner, M.D., M.S., a principal investigator on GO MOMs and director of the Division of Maternal-Fetal Medicine at Women & Infants Hospital. Dr. Werner is also a member of the Hassenfeld Institute’s executive committee.
GO MOMs builds on a previous NIH-funded landmark study of hyperglycemia and adverse pregnancy outcomes and its follow-up, HAPO and HAPO-FUS, which found that people with elevated blood glucose during pregnancy – even if not high enough to meet the definition of gestational diabetes – are significantly more likely to develop type 2 diabetes or prediabetes years after pregnancy than their counterparts without elevated blood glucose.
In addition, HAPO-FUS demonstrated that children born to people with elevated blood glucose during pregnancy were more likely to have obesity and impaired glucose metabolism a decade later. The effects in children, called metabolic imprinting, are thought to occur much earlier during pregnancy than when gestational diabetes is currently screened.
The data collected from GO MOMs will help determine timing and approach for future clinical trials to understand when and how to screen for and treat elevated blood glucose in pregnancy, and if this treatment will have any effect on children years later.
“By the time people are currently screened for gestational diabetes, it could be too late to avoid the long-lasting health effects,” said Dr. William Lowe, professor of medicine at Northwestern University Feinberg School of Medicine, Chicago, and study chair for GO MOMs. “We hope to recruit a diverse group of GO MOMs participants to help pinpoint key changes during pregnancy and see if there are associations with a subsequent gestational diabetes diagnosis and large size at birth for the offspring.”
Northwestern University is the study’s coordinating center and a study site. Other study locations include:
- Columbia University, New York
- Kaiser Center for Health Research, Honolulu
- Kaiser Center for Health Research NW, Portland, Oregon
- Magee Women’s Hospital, Pittsburgh
- Massachusetts General Hospital, Boston
- Tufts University, Boston
- Women and Infants Hospital of Rhode Island, Providence
- Yale University, New Haven, Connecticut
“GO MOMs will provide precise insight into glucose changes during pregnancy, informing future innovations in diabetes prevention,” said NIDDK Director Dr. Griffin P. Rodgers. “This study sets the stage for healthier generations to come.”
The study is open now for people in their first trimester of pregnancy without diabetes and willing to use a continuous glucose monitoring device for 10 days at four times during their pregnancy. To learn more and enroll, www.GoMomsStudy.org.
GO MOMs is funded by the NIDDK. Dexcom is providing the continuous glucose monitors.